005500.KO Samjin Pharm
- Market cap
- KRW 258B
- P/E
- 11.8x
- P/B
- 0.87x
- ROE
- 5.0%
- Dividend yield
- 3.81%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 005500.KO undervalued?
Graham number005500.KO trades 32.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Samjin Pharm fundamental analysis
No fundamental analysis for Samjin Pharm yet.
Samjin Pharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry e…
Full company profileSamjin Pharm financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Samjin Pharm annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 239B | 245B | 260B | 242B | 235B | 250B | 274B | 292B | 308B | 309B | 295B |
| Gross Profit | 129B | 136B | 143B | 121B | 111B | 118B | 118B | 117B | 129B | 125B | 105B |
| Operating Income | 42.1B | 46.9B | 59.5B | 44.9B | 32.2B | 33.9B | 23.2B | 20.5B | 31.6B | 26.8B | 21.5B |
| EBITDA | - | 53.3B | 66.3B | 28.4B | 39.4B | 42.4B | 36.8B | 36.6B | 65.9B | 46.9B | 43.0B |
| Net Income | 30.2B | 35.8B | 25.5B | 11.9B | 27.9B | 28.4B | 21.9B | 18.9B | 39.2B | 24.2B | 15.0B |
| EPS | - | 2,910 | 2,075 | 966 | 2,266 | 2,309 | 1,655 | 1,480 | 3,132 | 1,909 | 1,184 |
| Balance Sheet | |||||||||||
| Total Assets | 228B | 242B | 250B | 244B | 269B | 332B | 407B | 420B | 425B | 471B | 477B |
| Total Liabilities | 57.9B | 48.4B | 45.0B | 46.7B | 55.6B | 98.3B | 131B | 155B | 164B | 180B | 178B |
| Shareholders' Equity | 170B | 193B | 205B | 197B | 213B | 234B | 275B | 265B | 262B | 290B | 299B |
| Cash & Short-term Investments | 11.9B | 21.9B | 30.7B | 31.9B | 18.9B | 7.94B | 2.34B | 2.40B | 3.42B | 12.1B | 12.8B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 48.7B | 37.3B | 30.1B | 23.6B | 23.9B | 24.0B | 17.3B | 8.33B | 38.2B | 24.1B | 54.1B |
| Capital Expenditure | 7.80B | 8.86B | 8.24B | 12.0B | 30.6B | 74.6B | 35.5B | 20.7B | 18.3B | 14.5B | 8.31B |
| Free Cash Flow | - | 28.1B | 21.8B | 11.6B | -6.74B | -50.6B | -18.2B | -12.4B | 19.8B | 9.62B | 45.8B |
| Ratios | |||||||||||
| ROE | 17.8% | 18.5% | 12.4% | 6.0% | 13.1% | 12.1% | 8.0% | 7.1% | 15.0% | 8.3% | 5.0% |
| ROA | 13.3% | 14.8% | 10.2% | 4.9% | 10.4% | 8.5% | 5.4% | 4.5% | 9.2% | 5.1% | 3.1% |
| Net Profit Margin | 12.6% | 14.6% | 9.8% | 4.9% | 11.9% | 11.4% | 8.0% | 6.5% | 12.7% | 7.8% | 5.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Samjin Pharm dividends
- Dividend yield
- 3.81%
- Forward dividend
- 800.00 KRW
- Payout ratio
- 40.6%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 9.81B | 775 | 40.6% |
| 2024 | KRW 10.2B | 816 | 26.0% |
| 2023 | KRW 10.6B | 829 | 56.0% |
| 2022 | KRW 9.84B | 744 | 45.0% |
| 2021 | KRW 9.84B | 800 | 34.7% |
| 2020 | KRW 9.84B | 800 | 35.3% |
| 2019 | KRW 9.84B | 800 | 82.8% |
| 2018 | KRW 9.84B | 800 | 38.6% |
| 2017 | KRW 8.72B | 709 | 24.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.03121:1 on Dec 29, 2010.
Who owns Samjin Pharm
- Insiders 37.41%
- Institutions 1.55%
- Public & others 61.04%
- Shares outstanding 12.7M
- Free float 7.94M
Samjin Pharm company profile
- Company name
- Samjin Pharm
- Ticker
- 005500.KO
- ISIN
- KR7005500004
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 586
- Fiscal year end
- December
- Address
- 121 Wausan Ro, Seoul, South Korea, 04054
- Phone
- 82 2 3140 0700
- Website
- samjinpharm.co.kr
About Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Samjin Pharm management
5- Mr. Kyu Seok ChoPresident, CEO & Chairman · born 1971
- Ms. Ji-hyeon ChoiPresident, CEO & Director · born 1974
- Mr. Kyu Hyung ChoVP, Internal Director & Head of Sales · born 1975
- Ms. Jee Sun ChoiVP & Internal Director · born 1977
- Mr. Kim Jung-ilProduction Head · born 1961